Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 271

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 2
Chunk 271
---
 that existed at the balance sheet date. Accordingly,
the Company determined that the fair value of the equity securities on the date of the Fourth Securities Purchase Agreement of April 21,
2025 and June 30, 2025 was equal to $500,000.

On June 5, 2025, the Company sold an additional 938 shares of Series D Preferred Stock for gross cash proceeds of $750,400
in an additional closing of the Fourth PIPE Financing.

32

On June 25, 2025, the Company
entered into an amendment to the Fourth Securities Purchase Agreement pursuant to which the Company added certain new institutional investors
to the schedule of buyers in the Fourth Securities Purchase Agreement, to issue and sell to such investors, in one or more closings shares
of the Company’s Series D Preferred Stock. Also, on June 25, 2025, the Company sold an additional 2,315 shares of Series D Preferred
Stock for gross cash proceeds of $1,852,000 in an additional closing of the Fourth PIPE Financing. On July 18, 2025, the Company sold
an additional 497 shares of Series D Preferred Stock for gross cash proceeds of $432,600 in an additional closing of the Fourth PIPE
Financing.

July
2025 ELOC Transaction

On
July 11, 2025, the Company entered into an agreement to issue and sell 12,500,000 shares of Common Stock under the New Keystone Purchase
Agreement. As the New Keystone Purchase Agreement constitutes a continuation of the equity line program commenced under the February
2024 Purchase Agreement, the Commitment Shares issued to the Investor pursuant to the February 2024 Purchase Agreement shall satisfy
in full the Company’s obligation to deliver any additional shares of Common Stock to the Investor as consideration for entering into
the New Keystone Purchase Agreement.

Orphan Drug Designation

In
July 2025, CER-1236 received an FDA Orphan Drug Designation for the treatment of acute myeloid leukemia.

Nasdaq
Notices of Non-compliance and Nasdaq Panel Decision

As
previously disclosed, on January 17, 2025, the Company received a letter setting forth the determination of a panel convened by Nasdaq
(the “Nasdaq Panel”) granting the Company’s request for an extension (the “Extension”) to regain compliance
with certain continued listing requirements of the Nasdaq Stock Market until April 22, 2025. The Company presented its plan